Pharmaceutical Drug Delivery Market Upcoming Trends, Competitors and Key Players Bayer, Pfizer, Novartis, Sanofi, Antares Pharma,Accord Healthcare,Abbott, and GSK

Controlled release drug delivery systems allow reduction in amount of dose and dosage frequency, enhanced patient compliance and acceptance, less fluctuation in plasma drug levels, uniform drug effect, and improved efficacy ratio of administered therapeutic. In comparison to conventional delivery, these systems achieve a prolonged therapeutic effect, increase predictability in drug release kinetics, and bring about delivery at a pre-determined rate locally or systematically. Thus, with several added advantages offered by these systems, their adoption is slated to increase at a noteworthy rate over the coming years.

Oral controlled drug release systems are unique in formulation and are meticulously developed for usage in treatment and management of disorders. Since these require minimal dosage frequency, they are easy to administer to patients. Since these therapeutics provide increased compliance, treatment of chronic diseases also prove to be simplified with their adoption. Thus, many developers in the market are focusing on systems that cater to such specific therapeutics intended for use in geriatric and pediatric patients. The trend is estimated to fuel growth prospects

Increasing approval of new drugs from U.S. FDA is expected to drive growth of the global pharmaceutical drug delivery market. For instance, in April 2019, the U.S. Food and Drug Administration (FDA) announced the approval of Duobrii (contains-halobetasol propionate and tazarotene), which is used for the treatment of plaque psoriasis. It is manufactured by Ortho Dermatogics Company.

Request A Sample Copy:
https://www.coherentmarketinsights.com/insight/request-sample/2633

Furthermore, new product launches is expected to boost the global pharmaceutical drug delivery market. For instance, in August 2018, Sanofi Genzyme launched new drug (Aubagio) for the treatment of multiple sclerosis. Aubagio offers once-a-day treatment and ease of convenience for the patient.

Moreover, in April 2019, Pfizer launched trastuzumab (trazimera) for the treatment of metastatic HER2 (Human Epidermal Growth Factor2)-positive breast cancer and HER2-positive metastatic gastric cancer. Hence, these products are expected to boost the global pharmaceutical drug delivery market.

Based on route of administration, the pharmaceutical drug delivery industry is segmented into oral, pulmonary, injectable, ocular, nasal, topical, implantable, and transmucosal drug delivery. The Topical Drug Delivery market is expected to grow at the highest CAGR during the forecast period. Growth in this segment can be attributed to the wide range of advantages associated with this route of administration, including convenience and ease of use, right dosage to the right place, painless and noninvasive delivery, superior spreadability, and enhanced patient compliance.

Growing demand for biosimilars to drive the market for conventional injection devices
Based on type, the Injectable Drug Delivery technology market is segmented into conventional injection devices, self-injection devices, and other devices. The conventional injection devices segment accounted for the largest market share in 2018. The large share of this segment is due to the increasing prevalence of chronic diseases (particularly cancer and diabetes) and CVD, growing demand for biosimilar products, and low cost of devices and manufacturing.

On the basis of region, global pharmaceutical drug delivery market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

North America is expected to hold dominant position in the global pharmaceutical drug delivery market, owing to increasing research and development activities in the region. For instance, in April 2019, Abbvie Pharmaceutical received an approval from U.S. Food and Drug Administration (FDA) for a new drug known as SKYRIZI (risankizumab), which is used for the treatment of Plaque Psorisis.

Furthermore, Asia Pacific is also projected to witness significant growth in the global pharmaceutical drug delivery market during the forecast period, owing to increasing new launches of products. For instance, in April 2019, Glenmark launched its anti-diabetic medicine (SGLT2 inhibitor Remogliflozin) in India. This drug is used for the treatment of type-2 diabetes mellitus in adults. It is administered via oral route.

Key players operating in the global pharmaceutical drug delivery market include Johnson and Johnson, Merck & Co, Inc., Bayer AG, Pfizer, Inc., Novartis AG, Sanofi, Antares Pharma, Inc., Accord Healthcare, Inc., Abbott, and GSK.

Buy This Business Report:
https://www.coherentmarketinsights.com/insight/buy-now/2633

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.